Aspirin and Plavix (dual therapy) is recommended up to about a year after a stent(s) implant to help prevent any clots from forming at the site of the implant. Circumstances may exist that continued plavix medication may be prescribed for longer periods of time.
Structual collapse of a stent would indicate an improper size or defect. I discontinued plavix after year, and I have never heard of plavix associated with a collapsed stent! There may be a misunderstanding.
I agree with Kenkeith. My husband only had to take his for one year after stenting. I've also never heard of a stent collapsing if not on the Plavix, it's used to prevent blood clots after stenting which has nothing to do with the stent collapsing.
First it was recommended to take plavix for three months, then six, then twelve and more recently 18months to two years. There are some cardiologists who argue it should be taken for life. Why? because some patients have developed clots in drug eluting stents when plavix has been stopped, even after a year. Some people seem more prone to this than others and the reasons have yet to be identified. I think it's just a choice of words problem here, collapse is being used as in failing to perform its intended task.
Obviously, there was minunderstanding regarding the word collapse!. And plavix use prior to a DES implant has been a subject of indesiveness and uncertainty since the introduction of drug eluding stents....subject of many threads on this forum. "Why" longer term therapy has been asked?
There has been a recent study designed to evaluate the relationship between clopidogrel (plavix) use and long-term rates of cardiac death or MI after DES implantation.
".....stopped taking clopidogrel and were followed up for an additional 12 months. At 18-month follow-up, there was no difference between patients with a drug-eluting or bare-metal stent in cumulative rates of death or myocardial infarction (MI). However, after clopidogrel discontinuation patients receiving drug-eluting vs bare-metal stents experienced higher rates of death and MI (4.9% vs 1.3%, respectively). These results have created uncertainty regarding the minimal necessary duration of antiplatelet therapy after drug-eluting stent implantation. Also, there remains widespread uncertainty regarding the risk of clinical events after the discontinuation of clopidogrel, particularly after DES implantation.
This risk or any risk associated with plavix needs to be evaluated for excessive bleeding, etc. (for some individuals that is a serious consideration) vs. a risk for an MI. Apparently, OP experiences other problems believed to be associated with plavix and that should also be a consideration for him. I discontinued plavix after a year or so and my wallet is happy.